---
source_url: https://cps.pharmacists.ca/print/new/documents/MA_CHAPTER/en/conjunctivitis
content_type: minor_ailments
document_id: conjunctivitis
source_system: CPS (Canadian Pharmacists Association)
processed_at: '2025-05-29T07:19:26.935482Z'
processing_stage: url_preservation_final
pipeline_version: '1.0'
download_date: unknown
converted_from: conjunctivitis.html
redownload_instructions:
  method: Use unified downloader
  command: python cps_unified_downloader.py --types minor_ailments
  note: Requires valid CPS access credentials
---

# Conjunctivitis

### Conjunctivitis

|  |
| --- |
| Anne M. Friesen, BSc(Pharm), MSc |
| Date of Revision: March 28, 2024 |
| Peer Review Date: August 15, 2018 |


#### Pathophysiology

The conjunctiva is a thin, translucent, relatively elastic tissue layer that lines the inside of the eyelids (palpebral portion) and the anterior aspect of the globe (bulbar portion) (see Eyelid Conditions: Hordeolum, Chalazion and Blepharitis, Figure 1). As the outermost layer of the exterior surface of the globe, the conjunctiva is exposed to many microorganisms and other environmental factors. The combined action of the tears and eyelids protects the conjunctiva by trapping and diluting debris and organisms, then flushing the tears into the nasolacrimal duct.â€‹[^[1]]â€‹[^[2]]

Conjunctivitis is a general term that refers to any inflammatory condition of the membrane that lines the inside of the eyelids and covers the exposed surface of the sclera. The inflammation can be hyperacute, acute or chronic in presentation and may be caused by infection or many other factors (see Table 1). Conjunctivitis is the most common worldwide cause of red eye.â€‹[^[2]]â€‹[^[3]] This chapter addresses bacterial (hyperacute, acute and chronic), viral and allergic conjunctivitis.

|  |  |
| --- | --- |
| Bacterial | Neonates: Chlamydia trachomatis, Staphylococcus aureus, Haemophilus influenzae, Streptococcus pneumoniae, Neisseria gonorrhoeae, Neisseria meningitidis |
| Children: H. influenzae, S. pneumoniae, S. aureus |  |
| Adults: S. aureus, coagulase-negative Staphylococcus organisms, H. influenzae, S. pneumoniae, N. gonorrhoeae, N. meningitidis, C. trachomatis |  |
| Viral | AdenovirusHerpes simplex virusHuman papillomavirus |
| Immunologic | Immediate hypersensitivity reactions: hay fever, vernal keratoconjunctivitis, atopic keratoconjunctivitis, giant papillary conjunctivitis |
| Autoimmune disease: keratoconjunctivitis sicca with SjÃ¶gren syndrome, ocular cicatricial pemphigoid |  |
| Delayed hypersensitivity reactions |  |
| Chemical or irritative | Iatrogenic: miotics, idoxuridine, preservatives, contact lens solutions |
| Occupational: acids, alkalies, smoke, wind, UV light |  |
| Irritative: superior limbic keratoconjunctivitis |  |
| Associated with dermatologic condition | Ocular rosaceaPsoriasisStevens-Johnson syndrome (erythema multiforme major) |
| Associated with systemic disease | Thyroid diseaseKawasaki disease |
| Lacrimal system infections | CanaliculitisDacryocystitis |


#### Goals of Therapy



#### Patient Assessment

An algorithm for the assessment of eye conditions is presented in Assessment of Patients with Eye Conditions.

Typically, patients present with some degree of redness in the conjunctiva, as well as some type of discharge. Other descriptions of symptoms include a scratching or burning sensation, a foreign body sensation, a feeling of fullness around the eyes, itching, and mild photophobia. Often the eyes are crusty or sticky after sleeping, particularly with bacterial conjunctivitis.

Signs and symptoms of the most common types of conjunctivitis are listed in Table 2.

| Clinical Findings | Viral | Bacterial | Allergic |
| --- | --- | --- | --- |
| Itching | Minimal | Minimal | Severe |
| Redness | Generalized | Generalized | Generalized |
| Discharge | Profuse, serous | Moderate, mucopurulent or purulent | Moderate, serous or mucoid |


#### Acute Bacterial Conjunctivitis

#### Introduction

Approximately 60% of suspected and documented cases of bacterial conjunctivitis resolve spontaneously in 1â€“2 weeks.â€‹[^[8]] Bacteria may be eradicated in 5 days with a 7-day course of antibiotics.â€‹[^[9]]  Antibiotic treatment may also decrease the risk of more serious corneal complications, recurrences and person-to-person spread.â€‹[^[2]]â€‹[^[3]]â€‹[^[5]]â€‹[^[10]]â€‹[^[11]]â€‹[^[12]]â€‹[^[13]] The practice of delayed antibiotics (patients are given an antibiotic prescription to fill 3 days after being assessed, if needed) demonstrated 50% less antibiotic use than immediate antibiotics.â€‹[^[14]] Moderate symptoms persisted only half a day longer in the delayed group. The most common causative organism is Staphylococcus aureus, but Streptococcus pneumoniae and Haemophilus influenzae are also common, especially in children.â€‹[^[1]]â€‹[^[5]]â€‹[^[15]]â€‹[^[16]]â€‹[^[17]] 

#### Nonpharmacologic Therapy



#### Pharmacologic Therapy

For comparative ingredients of nonprescription products, consult the *Compendium of Products for Minor Ailments*â€”Ophthalmic Products: Anti-infectives.

For mild cases of bacterial conjunctivitis in adults, **polymyxin B/gramicidin** eye drops can be used; generally, continue treatment for 2 days after symptoms have resolved.â€‹[^[1]]â€‹[^[2]]â€‹[^[3]]â€‹[^[5]]â€‹[^[10]]â€‹[^[16]]â€‹[^[18]]â€‹[^[19]]

Polymyxin B-based combinations are not reliably bactericidal.â€‹[^[19]] If there is no improvement within 48 hours of starting treatment, refer the patient to a physician or eye-care practitioner.

When the infection is moderate to severe, or if polymyxin-based products have been ineffective, the use of standard empiric treatment with broad spectrum antibacterial drops is warranted (e.g., **trimethoprim/polymyxin B** ophthalmic drops, erythromycin ophthalmic ointment, fusidic acid ophthalmic drops).â€‹[^[5]]â€‹[^[10]]â€‹[^[16]]â€‹[^[18]] Adults and adolescents generally prefer ophthalmic drops. Ointments may be better tolerated by young children, who may not be bothered by ointment-induced blurred vision and may find drop administration irritating.

Tobramycin provides good gram-negative coverage and relatively poor gram-positive coverage with systemic use but is sufficiently effective in the topical treatment of conjunctivitis. Toxicity to the corneal epithelium can occur, especially with prolonged use. Reserve fluoroquinolone antibiotics (ciprofloxacin, gatifloxacin, moxifloxacin, ofloxacin) for serious infections such as bacterial keratitis.â€‹[^[1]]â€‹[^[2]]â€‹[^[3]]â€‹[^[5]]â€‹[^[10]]â€‹[^[16]]â€‹[^[18]]

For more information on ophthalmic antibacterials, see Table 4. 

#### Hyperacute Bacterial Conjunctivitis

#### Introduction

This infection is most commonly seen in neonates or sexually active young people (15â€“24 years of age).â€‹[^[2]]â€‹[^[3]]â€‹[^[5]]â€‹[^[10]]â€‹[^[15]]â€‹[^[18]] It is a severe, sight-threatening ocular infection caused by Neisseria gonorrhoeae or Neisseria meningitidis. It is characterized by a copious, yellow-green purulent discharge, redness, irritation and tenderness to palpation. Symptoms are rapidly progressive, leading to severe corneal damage, perforation and loss of vision if there is any delay in treatment. In adults, the organism is usually transmitted from the genitalia to the hands and then to the eyes. In infants, transmission of the organism occurs during vaginal delivery, and they typically develop bilateral discharge 3â€“5 days after birth. As a preventive measure, ophthalmic antibiotic ointments have been routinely applied to infants immediately after delivery; however, the Canadian Paediatric Society currently recommends abolishing the mandatory application of antibiotic ophthalmic ointment to newborns.â€‹[^[20]] Instead, it recommends screening all pregnant women for gonorrhea and chlamydia, and subsequently treating infants with effective antibiotics if the mother has an untreated infection at time of delivery.

#### Nonpharmacologic Therapy

Immediate medical assessment is required. After treatment has been initiated, the same adjunctive nonpharmacologic measures as used for acute bacterial conjunctivitis can be implemented.â€‹[^[2]]â€‹[^[5]]â€‹[^[18]]

#### Pharmacologic Therapy

Medical assessment is imperative. Treatment consists of immediate Gram staining of specimens, followed by systemic and ophthalmic antibacterials and saline irrigation. For more information on ophthalmic antibacterials, see Table 4.

#### Chronic Bacterial Conjunctivitis

#### Introduction

Chronic bacterial conjunctivitis is defined as a condition that lasts 4 weeks or longer. It is often associated with blepharitis, and is sometimes found in conjunction with facial seborrhea, acne rosacea, nasolacrimal duct obstruction or chronic dacryocystitis. S. aureus and Moraxella lacunata are most commonly involved, the latter occurring in clusters in women who share contaminated makeup.â€‹[^[4]]â€‹[^[18]]

In sexually active adults, chronic bacterial conjunctivitis can be a manifestation of a sexually transmitted infection involving Chlamydia trachomatis.â€‹[^[6]]

#### Nonpharmacologic Therapy

Treatment is similar to the treatment of blepharitis (see Eyelid Conditions: Hordeolum, Chalazion and Blepharitis). Eyelid hygiene and warm compresses are important as a daily routine. Contaminated facial-care products and makeup should be discarded.â€‹[^[2]]â€‹[^[3]]â€‹[^[18]]

#### Pharmacologic Therapy

Chronic bacterial conjunctivitis has a protracted course with periods of exacerbation, and treatment should be carefully managed by an appropriate health-care practitioner.

Topical antibacterials are used during periods of exacerbation. Patients whose chronic conjunctivitis is associated with meibomian gland dysfunction or severe acne rosacea may benefit from oral agents such as doxycycline or erythromycin;â€‹[^[21]] for more information, see Eyelid Conditions: Hordeolum, Chalazion and Blepharitis. Topical metronidazole therapy for acne rosacea may also ameliorate associated conjunctivitis; for more information consult the *Compendium of Therapeutic Choices:* Rosacea. 

For more information on ophthalmic antibacterials, see Table 4. 

#### Viral Conjunctivitis

#### Introduction

Patients with viral conjunctivitis usually present with an acutely red eye, watery discharge, conjunctival swelling, foreign body sensation and mild photophobia. There may be tenderness around the preauricular node. Occasionally, patients may have subconjunctival hemorrhage.â€‹[^[3]]â€‹[^[22]] Both eyes may be affected at the same time, or the second eye may become infected a few days after the first. If this happens, the infection is usually more severe in the first eye.

The most common causative organism of viral conjunctivitis is adenovirus. Viral infections are highly contagious and can be spread through respiratory tract-to-eye, finger-to-eye or instrument-to-eye (physician's office) contact as well as via contaminated swimming pools. Some patients have an associated respiratory tract infection.â€‹[^[2]]â€‹[^[3]]â€‹[^[15]]â€‹[^[18]]â€‹[^[22]] The incubation period ranges from 2â€“14 days and the infection can last from 2â€“4 weeks.â€‹[^[15]] The eye remains contagious for up to 2 weeks after the second eye becomes involved.â€‹[^[5]]â€‹[^[9]]

*Herpes simplex *virus (HSV) and *herpes zoster* can also cause viral conjunctivitis. The risk of progressive keratitis is higher with these types of infections.

#### Nonpharmacologic Therapy

All patients with suspected viral conjunctivitis require medical assessment to determine the cause. 

Treatment of adenovirus conjunctivitis is supportive. Cold compresses may increase patient comfort.â€‹[^[23]] Instruct patients to avoid direct contact with others for at least 10 days after the onset of symptoms (in the second eye, when involved), although the period of infectivity may be as long as 14 days.â€‹[^[9]] Handwashing with soap and water (not sanitizer) and using separate towels from noninfected individuals are important for preventing transmission to others. Children should be kept out of school until there is no ocular discharge (approximately 1 week).â€‹[^[3]]â€‹[^[24]]

#### Pharmacologic Therapy

Ocular  lubricants may be useful in improving patient comfortâ€‹[^[23]] (see Dry Eye). **Ophthalmic antihistamines** or **decongestants** may help with severe itching, but are generally not indicated (see Table 5 and Table 6).

Antiviral agents are usually not indicated in adenovirus infection, although cidofovir (available only through Health Canadaâ€™s Special Access Programme) has been used successfully.â€‹[^[23]] Ophthalmologists may administer a one-time irrigation with povidone/â€‹iodine 5% ophthalmic solution to prevent the spread of adenoviral conjunctivitis.â€‹[^[25]] Corticosteroid eye drops are not commonly used, as they may prolong viral shedding and inhibit immunoclearance.â€‹[^[23]] They may be used post-infection as a treatment for visual opacities caused by subepithelial infiltrates. In many cases, however, these infiltrates return after the corticosteroid is discontinued. Treatment with cyclosporine ophthalmic solution may clear subepithelial infiltrates while bypassing the negative effects of long-term corticosteroid therapy.â€‹[^[25]] For more information on anti-inflammatory ophthalmic agents, see Dry Eye.

Although HSV conjunctivitis is a self-limited acute condition, corneal involvement requires treatment with **trifluridine** (an ophthalmic antiviral) as monotherapy or in combination with oral antivirals (acyclovir, famciclovir, valacyclovir). Conjunctivitis due to herpes zoster virus requires treatment with oral antivirals, although trifluridine maybe added on for patients with an insufficient response to oral therapy alone.â€‹[^[2]]â€‹[^[3]]â€‹[^[9]]â€‹[^[18]]â€‹[^[23]] As of December 2022, trifluridine ophthalmic solution is not available in Canada.

For more information on antiviral agents, see Table 4. 

#### Allergic Conjunctivitis

#### Introduction

Allergic conjunctivitis encompasses a group of ocular surface diseases that vary in severity, but are typically associated with Type I hypersensitivity reactions.â€‹[^[26]] Seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC) comprise approximately 95% of allergic conjunctivitis cases. Vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC) and giant papillary conjunctivitis (GPC) are more serious conditions that require assessment and management by an eye-care specialist. VKC commonly occurs in patients 3â€“8 years of age and resolves in 95% of patients when they reach young adulthood.â€‹[^[27]]â€‹[^[28]] AKC occurs along with atopic dermatitis and is more likely to lead to corneal complications.

In SAC, patients experience ocular itching, tearing, redness and mild eyelid swelling.â€‹[^[2]]â€‹[^[3]]â€‹[^[4]] Although ragweed is the most common airborne cause of allergic rhinitis, grass pollen is considered the most common cause of ocular symptoms.â€‹[^[29]]â€‹[^[30]] Dry eye can also be a factor in SACâ€”reduced tear volume leads to decreased capacity to dilute and wash away allergens.

PAC exhibits the same symptoms as SAC, but reactions are triggered by environmental allergens commonly found in the home (e.g., dust mites, mould spores, animal dander). Patients suffer throughout the year, but may have seasonal exacerbations in addition to chronic symptoms.â€‹[^[31]]

Although other ocular conditions (e.g., blepharitis, dry eye) present similarly, the hallmark symptom of SAC is ocular itching, while patients with PAC have red eyes as their primary symptom.â€‹[^[26]] For further information on allergic conjunctivitis in relation to allergic rhinitis, see Allergic Rhinitis.

#### Nonpharmacologic Therapy

Allergen avoidance is an important first step in the treatment of allergic conjunctivitis.â€‹[^[32]]â€‹[^[33]] In SAC, minimize exposure to grassy fields, trees and flowers and keep windows closed to prevent pollens from entering the home. Wash hands after being outdoors and avoid touching/rubbing the eyes while outdoors. Wraparound eyeglasses are an effective means to protect the eyes from pollens and reduce symptoms of SAC.â€‹[^[34]]

In PAC, allergen avoidance may be more problematic as it could involve the family pet.â€‹[^[31]] However, dust mite control measures, proper ventilation of home and office environments, air filtration systems, and awareness of allergen prevalence (pollen and mould counts) can all help to ease symptoms. Washing hair prior to going to bed can also help reduce allergen exposure.

Cold compresses over the eyes offer considerable symptom relief, especially with ocular pruritus.â€‹[^[33]] 

#### Pharmacologic Therapy

For comparative ingredients of nonprescription products, consult the *Compendium of Products for Minor Ailments*â€”Ophthalmic Products: Anti-allergy Agents, Antihistamines and Decongestants; Ocular Lubricants.

Ocular  lubricants help to wash out allergens and may act as a barrier to pollens.â€‹[^[33]] Benzalkonium chloride (a preservative in some lubricants) may irritate eyes, especially if used â‰¥4 times per day; avoid when possible. Saline or commercial eyewashes can help wash out allergens and reduce eyelid swelling, chemosis (conjunctival edema) and hyperemia (redness due to increased blood flow). These are both first-line treatment options; refrigeration may improve their soothing effect. For more information on available ocular lubricants, see Dry Eye.

Ophthalmic **decongestants** (e.g., naphazoline, phenylephrine, tetrahydrozoline) decrease eye redness and eyelid edema through vasoconstriction. They may cause rebound ocular congestion with prolonged use (time frame not clearly defined, but probably with use >10 days).â€‹[^[35]] If rebound congestion occurs, it is likely to be mild and harmless.â€‹[^[35]] Ophthalmic decongestants are second-line treatment options for mild-moderate SAC; they are not indicated for prolonged use in PAC. Because they are vasoconstrictors, they are contraindicated in patients with narrow angle (angle-closure) glaucoma. For more information on ophthalmic decongestants, see Table 6.

Brimonidine, a selective alpha2-adrenergic receptor agonist typically used for glaucoma, is available without a prescription in a lower concentration (0.025%) for the treatment of red eye. Based on limited preliminary evidence, brimonidine does not appear to cause significant rebound hyperemia or tachyphylaxis.â€‹[^[36]]â€‹[^[37]]

**Oral H1** **antihistamines** may relieve itching associated with SAC but do not decrease redness.â€‹[^[32]] Ophthalmic antihistamines are available in combination with decongestants (e.g., pheniramine in combination with decongestants listed above) and are preferred over systemic antihistamines because they act faster and are less drying.â€‹[^[33]]â€‹[^[38]] 

Mast cell stabilizers prevent degranulation of mast cells and are useful in both SAC and PAC as they treat the late phase of the allergic response.â€‹[^[26]] Regular use during allergy season will prevent redness, itching and eyelid edema. Mast cell stabilizers may take up to 10 days for maximum effect; they must be started before allergy season to prevent symptoms. Lodoxamide and sodium cromoglycate are mast cellâ€“stabilizing agents that alleviate the signs and symptoms of mild to moderate allergic conjunctivitis.â€‹[^[2]]â€‹[^[30]]â€‹[^[32]]â€‹[^[38]]â€‹[^[39]] 

Agents that have both antihistaminic and mast cellâ€“stabilizing properties (e.g., olopatadine, ketotifen) will relieve itching quickly while providing long-term activity against ocular irritation by allergens.â€‹[^[26]]

For more information on ophthalmic antihistamines and mast cell stabilizers, see Table 5. 

Nonsteroidal anti-inflammatory eye drops such as ketorolac can decrease the amount of ocular itching and conjunctival redness in allergic conjunctivitis.â€‹[^[2]]â€‹[^[30]]â€‹[^[32]] These agents may cause stinging upon instillation; limit to short-term use to avoid serious corneal effects such as keratitis, ulceration or even corneal perforation. Patients at increased risk of corneal effects include those with dry eye syndrome and those recovering from recent surgery. For more information on ophthalmic NSAIDs, see Table 7.

Once the immediate problem of allergic symptoms is addressed, question the patient about possible dry eye symptoms. Patients with moderate to severe allergic conjunctivitis or those who do not respond to self-care measures within 72 hours require further medical assessment. Severe cases of SAC and VKC may require the use of topical  corticosteroids or other immunomodulatory agents (e.g., cyclosporine, lifitegrast) under the care of an ophthalmologist.â€‹[^[30]]â€‹[^[32]] For more information on anti-inflammatory ophthalmic agents, see Dry Eye.

#### Monitoring of Therapy

Table 3 provides a monitoring plan that should be individualized for the patient and the condition.

| Eye Condition | Monitoring | Goals/Endpoint of Therapy | Actions |
| --- | --- | --- | --- |
| Bacterial conjunctivitisâ€‹[5]â€‹[18] | Patient: dailyHealth-care practitioner: within 2 days of initiating drug therapy | Resolution of infection.A decrease in signs and symptoms within 48 h. | Adults: requires consultation for further therapy if worsening or no improvement within 48 h.Children: requires consultation for further therapy. Do not recommend self-treatment. |
| Chronic bacterial conjunctivitisâ€‹[5]â€‹[18] | Patient: dailyHealth-care practitioner: each visit | Control of infection.Risk reduction of long-term complications. | Encourage lid hygiene regimen (see Eyelid Conditions: Hordeolum, Chalazion and Blepharitis). Remind patient to cleanse only the margin of the eyelid and not to scratch the eyeball or conjunctiva. Requires consultation for further therapy if recurrence or acute exacerbation occurs. |
| Viral conjunctivitis (adenovirus)â€‹[18] | Patient/family: dailyHealth-care practitioner: within 1 wk of initiating treatment | Ease symptoms while infection resolves.Prevent transmission to others. | Requires medical assessment to rule out other viral causes.If decongestant or lubricant drops cause irritation, discontinue use or suggest a preservative-free product. |
| Seasonal allergic conjunctivitisâ€‹[29]â€‹[40] | Patient: dailyHealth-care practitioner: within 3 days of initiating drug therapy | Ease patient discomfort.Stop allergic/inflammatory process.Prevent recurrence in future seasons. | If decongestant or lubricant drops cause irritation, discontinue use or suggest a preservative-free product.Requires consultation for further therapy if no improvement within 3 days or if symptoms persist despite treatment.Requires consultation for further therapy if symptoms are severe. |


#### Algorithms

Algorithms for the assessment and management of conjunctivitis can be found in Red Eye, Figure 1 and Figure 2:  Assessment of Red Eye.

#### Drug Tables


**Drug Class: Antibacterials, ophthalmic**


**Drug Class: Antivirals, systemic**

| Drug/â€‹Cost[a] | Dosage | Adverse Effects | Comments |
| --- | --- | --- | --- |
| **besifloxacin** (Besivance) | 1 drop in affected eye(s) TID Ã— 5â€“7 days | Antibacterials: chronic use may cause corneal epithelial toxicity, allergy and bacterial resistance. | Fluoroquinolones should be reserved for serious corneal infections. |
| **ciprofloxacin** (Ciloxan, generics) | Drops: 1â€“2 drops Q2H while awake Ã— 2 days then 2 drops Q4H while awake Ã— 5 daysOintment: 1.25 cm TID Ã— 2 days then BID Ã— 5 days | Antibacterials: chronic use may cause corneal epithelial toxicity, allergy and bacterial resistance. | Fluoroquinolones should be reserved for serious corneal infections. |
| **erythromycin** (generics) | Ointment: 1.25 cm 2â€“6 times/day | Antibacterials: chronic use may cause corneal epithelial toxicity, allergy and bacterial resistance. |  |
| **fusidic acid** (Fucithalmic) | 1 drop Q12H Ã— 7 days | Antibacterials: chronic use may cause corneal epithelial toxicity, allergy and bacterial resistance. | Due to its broad-spectrum and BID dosing, fusidic acid is especially useful in children and elderly patients.Enterobacteriaceae and pseudomonas are resistant to fusidic acid. |
| **gatifloxacin** (Zymar) | First 2 days: 1 drop in affected eye(s) Q2H while awake, up to 8 times dailyDays 3â€“7: 1 drop QID | Antibacterials: chronic use may cause corneal epithelial toxicity, allergy and bacterial resistance. | Fluoroquinolones should be reserved for serious corneal infections. |
| **gramicidin** (Polysporin, generics) | Drops: initially 1â€“3 drops Q1H, gradually decreasing to 1â€“2 drops 4â€“6 times daily | Antibacterials: chronic use may cause corneal epithelial toxicity, allergy and bacterial resistance. | Limit use to 4â€“5 days.Choose broad-spectrum agent first, guided by patient allergies. |
| **moxifloxacin** (Vigamox, generics) | 1 drop TID Ã— 7 days | Antibacterials: chronic use may cause corneal epithelial toxicity, allergy and bacterial resistance. | Fluoroquinolones should be reserved for serious corneal infections. |
| **ofloxacin** (Ocuflox, generics) | 1â€“2 drops Q2â€“4H Ã— 2 days then QID Ã— 5 days | Antibacterials: chronic use may cause corneal epithelial toxicity, allergy and bacterial resistance. | Fluoroquinolones should be reserved for serious corneal infections. |
| **polymyxin B** (Polytrim, generics) | Initially 1â€“3 drops Q1H, gradually decreasing to 1â€“2 drops 4â€“6 times daily | Antibacterials: chronic use may cause corneal epithelial toxicity, allergy and bacterial resistance. |  |
| **tobramycin** (Tobrex, generics) | Drops: 1â€“2 drops Q4HOintment: 1.25 cm BIDâ€“TID | Antibacterials: chronic use may cause corneal epithelial toxicity, allergy and bacterial resistance. |  |
| **acyclovir** (Zovirax, generics) | Herpes zoster: 800 mg 5 times/day PO Ã— 7 days Herpes simplex: 200â€“400 mg 5 times/day PO Ã— 7â€“14 daysâ€‹[9] | GI upset (uncommon); well tolerated. |  |
| **famciclovir** (Famvir, generics) | Herpes zoster: 500 mg TID PO Ã— 7 daysHerpes simplex: 250 mg BID PO Ã— 7 daysâ€‹[9] | GI upset (uncommon); well tolerated. |  |
| **valacyclovir** (Valtrex, generics) | Herpes zoster: 1 g TID PO Ã— 7 daysHerpes simplex: 500 mg BID-TID PO Ã— 7 daysâ€‹[9] | GI upset (uncommon); well tolerated. |  |


**ðŸ«˜ Renal Monitoring - Monitor kidney function when using this medication**

<!-- AI_IMAGE_PLACEHOLDER: images/kidney.gif -->

![](images/ma-ON.gif)

<!-- AI_IMAGE_PLACEHOLDER: images/ma-ON.gif -->

gastrointestinal


**Drug Class: Antihistamines, ophthalmic**


**Drug Class: Mast Cell Stabilizers, ophthalmic**

| Drug/â€‹Cost[a] | Dosage | Adverse Effects | Comments |
| --- | --- | --- | --- |
| **antazoline** (Refresh, others) | 1â€“2 drops Q3â€“4H | Minor stinging on instillation; pupillary dilation and angle-closure glaucoma in predisposed persons, e.g., elderly, female, significantly hyperopic, have a positive family history, East Asian or Inuit ancestry (potentially due to shallower anterior chamber and angle anatomyâ€‹[41]â€‹[42]).Ophthalmic vasoconstrictors are meant for occasional and short-term use. Overuse may cause rebound hyperemia. | Antihistamine/ophthalmic vasoconstrictor combination. |
| **bepotastine besilate** (Bepreve) | 1 drop BID | Minor stinging on instillation.Mild or transient taste disturbances. | Mast cellâ€“stabilizing properties. |
| **ketotifen fumarate** (Zaditor, generics) | 1 drop Q8â€“12H | Minor stinging on instillation. | Mast cellâ€“stabilizing properties.Also available as a medication-releasing daily disposable contact lens. |
| **olopatadine 0.1%** (Patanol, generics) | 1â€“2 drops Q6â€“8H | Minor stinging on instillation. | Mast cellâ€“stabilizing properties. |
| **olopatadine 0.2%** (Pataday, generics) | 1 drop daily | Minor stinging on instillation. | Mast cellâ€“stabilizing properties. |
| **olopatadine 0.7%** (Pazeo) | 1 drop daily | Minor stinging on instillation. | Mast cellâ€“stabilizing properties. |
| **pheniramine** (Naphcon-A, Opcon-A, Visine, others) | 1â€“2 drops up to QID | Minor stinging on instillation; pupillary dilation and angle-closure glaucoma in predisposed persons, e.g., elderly, female, significantly hyperopic, have a positive family history, East Asian or Inuit ancestry (potentially due to shallower anterior chamber and angle anatomyâ€‹[41]â€‹[42]).Ophthalmic vasoconstrictors are meant for occasional and short-term use. Overuse may cause rebound hyperemia. | Antihistamine/ophthalmic vasoconstrictor combination. |
| **sodium cromoglycate** (Cromolyn) | 1â€“2 drops 4â€“6 times/day | Minor stinging on instillation. | Mast cell stabilizerâ€”does not provide immediate relief.May take 2â€“3 days to see symptom improvement. |
| **lodoxamide** (Alomide) | 1â€“2 drops QID | Minor stinging on instillation. | Mast cell stabilizerâ€”does not provide immediate relief.May take 2â€“3 days to see symptom improvement. |


![](images/ma-ON.gif)

<!-- AI_IMAGE_PLACEHOLDER: images/ma-ON.gif -->


**Drug Class: Vasoconstrictors/Decongestants, ophthalmic**

| Drug/â€‹Cost[a] | Dosage | Adverse Effects |
| --- | --- | --- |
| **naphazoline** (Clear Eyes, Refresh, others) | 1â€“2 drops Q3â€“4H PRN Ã— 3â€“4 days | Minor stinging on instillation; pupillary dilation and angle-closure glaucoma in predisposed persons, e.g., elderly, female, significantly hyperopic, have a positive family history, East Asian or Inuit ancestry (potentially due to shallower anterior chamber and angle anatomyâ€‹[41]â€‹[42]).Ophthalmic vasoconstrictors are meant for occasional and short-term use. Overuse may cause rebound hyperemia. |
| **phenylephrine** (Mydfrin, others) | 1â€“2 drops QID PRN Ã— â‰¤3 days | Minor stinging on instillation; pupillary dilation and angle-closure glaucoma in predisposed persons, e.g., elderly, female, significantly hyperopic, have a positive family history, East Asian or Inuit ancestry (potentially due to shallower anterior chamber and angle anatomyâ€‹[41]â€‹[42]).Ophthalmic vasoconstrictors are meant for occasional and short-term use. Overuse may cause rebound hyperemia. |
| **tetrahydrozoline** (Visine, others) | 1â€“2 drops BID-QID | Minor stinging on instillation; pupillary dilation and angle-closure glaucoma in predisposed persons, e.g., elderly, female, significantly hyperopic, have a positive family history, East Asian or Inuit ancestry (potentially due to shallower anterior chamber and angle anatomyâ€‹[41]â€‹[42]).Ophthalmic vasoconstrictors are meant for occasional and short-term use. Overuse may cause rebound hyperemia. |
| **brimonidine (0.025%)** (Lumify) | 1 drop Q6â€“8H PRN; maximum 4x/day | Pain on instillation. |


![](images/ma-ON.gif)

<!-- AI_IMAGE_PLACEHOLDER: images/ma-ON.gif -->


**Drug Class: NSAIDs, ophthalmic**

| Drug/â€‹Cost[a] | Dosage | Adverse Effects | Comments |
| --- | --- | --- | --- |
| **diclofenac** (Voltaren, generics) | 1 drop 4â€“5 times daily | Mild to moderate stinging on instillation; epitheliopathy and possible ulceration with prolonged and frequent use. |  |
| **ketorolac** (Acular, Acuvail, generics) | Acular (0.5%): 1 drop QIDAcuvail (0.45%): 1 drop BID | Mild to moderate stinging on instillation; epitheliopathy and possible ulceration with prolonged and frequent use. | Acuvail is available only in preservative-free single-use vials. |
| **nepafenac** (Nevanac, Ilevro) | Nevanac (0.1%): 1 drop TIDIlevro (0.3%): 1 drop once daily | Mild to moderate stinging on instillation; epitheliopathy and possible ulceration with prolonged and frequent use.Eyelid margin crusting, eye pain, punctate keratitis, blurred vision, dry eye, pruritis, headache. | Shake well before use.Contains benzalkonium chloride as a preservative. Contact lenses should not be worn when using nepafenac. |


#### Suggested Readings

American Academy of Ophthalmology. *Conjunctivitis PPP-2018*.

Narayana S, McGee S. Bedside diagnosis of the 'red eye': a systematic review. *Am J Med* 2015;128:1220-4.

Patel DS, Arunakirinathan M, Stuart A et al. Allergic eye disease. *BMJ* 2017;359:j4706.

Pflipsen M, Massaquoi M, Wolf S. Evaluation of the painful eye. *Am Fam Physician* 2016;93:991-8.

#### References


---

## Source Information

**Original Source:** [https://cps.pharmacists.ca/print/new/documents/MA_CHAPTER/en/conjunctivitis](https://cps.pharmacists.ca/print/new/documents/MA_CHAPTER/en/conjunctivitis)  
**Content Type:** minor_ailments  
**Processed:** 2025-05-29 07:19 UTC  
**Source System:** Canadian Pharmacists Association (CPS)

### How to Cite
> Canadian Pharmacists Association. *conjunctivitis*. 
> CPS Online. Retrieved 2025-05-29 07:19 UTC from https://cps.pharmacists.ca/print/new/documents/MA_CHAPTER/en/conjunctivitis


```

*Note: This document was processed using automated tools. Always refer to the original source for the most up-to-date information.*

---
*Document processed with CPS Pipeline v1.0 â€¢ [Source URL](https://cps.pharmacists.ca/print/new/documents/MA_CHAPTER/en/conjunctivitis)*
